The impact of extramedullary disease (EMD) in AML on the outcomes of allogeneic hematopoietic cell transplantation (alloHCT) is unknown. Using data from the Center for International Blood and Marrow Transplant Research, we compared the outcomes of patients who had EMD of AML at any time before transplant, with a cohort of AML patients without EMD. We reviewed data from 9797 AML patients including 814 with EMD from 310 reporting centers and 44 different countries, who underwent alloHCT between and 1995 and 2010. The primary outcome was overall survival (OS) after alloHCT. Secondary outcomes included leukemia-free survival (LFS), relapse rate and treatment-related mortality (TRM). In a multivariate analysis, the presence of EMD did not affect either OS (hazard ratio 1.00, 95% confidence interval (CI) 0.91-1.09), LFS (0.98, 0.89-1.09), TRM (relative risk 0.92, 95% CI 0.80-1.16, P = 0.23) or relapse (relative risk = 1.03, 95% CI, 0.92-1.16; P = 0.62). Furthermore, the outcome of patients with EMD was not influenced by the location, timing of EMD, or intensity of conditioning regimen. The presence of EMD in AML does not affect transplant outcomes and should not be viewed as an independent adverse prognostic feature.
INTRODUCTION
Extramedullary disease (EMD) in AML refers to disease found in organs or tissue outside the blood or bone marrow. The most common manifestations of EMD include myeloid sarcomas, leukemia cutis and meningeal leukemia. Although the exact frequency is unknown, EMD has been estimated to occur in 3%-8% of patients with AML, and has been reported to be more common in patients with core-binding factor leukemia, FAB M2/M4/M5, high WBC count and increased age. 1 Historically, the presence of EMD has been considered a poor prognostic feature in AML. 2 The impact of EMD may depend on the site of EMD as well as cytogenetic and molecular features. In adult patients with t (8:21), complete remission (CR) rates (50% vs 92%) and overall survival (OS; 5.4 vs 59.5 months) were markedly worse in patients with EMD treated with standard 7+3 regimens. 3 In a retrospective analysis of 434 Japanese patients with AML, myeloid sarcomas were associated with higher relapse rate and lower disease-free survival. 4 Owing to its potent antitumor effects, it has been suggested that allogeneic hematopoietic cell transplantation (alloHCT) could overcome the potentially poor prognostic impact of EMD in AML. However, data supporting this approach are limited. A retrospective study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire registry of 51 patients with myeloid sarcoma, who underwent allogeneic stem cell transplantation demonstrated an OS of 36% at 5 years, confirming that allogeneic stem cell transplantation is a valid therapeutic option. 5 Isolated EMD relapses are common following alloHCT in patients with AML, indicating a relative lack of graft versus leukemia effect in EMD sites. 6 Furthermore, reduced intensity conditioning regimens, T-cell-depleted grafts, or non-total body irradiation-based conditioning regimens have been associated with higher rates of EMD relapse and may reduce the effectiveness of alloHCT in AML with EMD disease. [7] [8] [9] [10] As a prospective study to determine the impact of alloHCT for AML with EMD is not feasible, the Center for International Blood and Marrow Transplant Research (CIBMTR) database offers a comprehensive data set, to identify factors that influence the outcome of alloHCT for AML with EMD. In this study, we compared the outcomes of patients who had EMD of AML at any time before transplant with a cohort of AML patients without EMD. We also examined disease-, treatment-and transplant-related characteristics that affected the outcomes of patients with EMD.
PATIENTS AND METHODS

Data source
The CIBMTR, a voluntary working group of more than 500 transplant centers worldwide, contributed data on consecutive alloHCTs to a statistical center housed both at the Medical College of Wisconsin (Milwaukee, WI, USA) and the National Marrow Donor Program (Minneapolis, MN, USA). Observational studies conducted by CIBMTR are performed with a waiver of informed consent and in compliance with Health Insurance Portability and Accountability Act regulations as determined by the Institutional Review Board and the Privacy Officer of the Medical College of Wisconsin.
Patient selection
The study population consists of AML patients between 18 and 70 years of age, who underwent bone marrow or peripheral blood alloHCT from either an HLA-identical sibling or unrelated donor between 1995 and 2010. Patients with acute promyelocytic leukemia were excluded.
The site of EMD was determined by the reporting center in one of four categories: the central nervous sytem, soft tissue, testes or other. The 'other' category was further subdivided into clinically relevant categories such as the 'skin' and the 'liver/spleen'. Pathologic or radiographic confirmation of EM disease was not required. Cytogenetics were classified according to Southwest Oncology Group/Eastern Cooperative Oncology Group (SWOG/ECOG) criteria. 11 Conditioning regimens were classified as myeloablative (MA), reduced intensity conditioning, or non-MA. 12, 13 CIBMTR classifications of unrelated donor matching were used to define well-matched, partially matched or mismatched categories.
Study end points and definitions
The primary outcome was OS after alloHCT (defined as the time from transplantation to death). Secondary end points included leukemia-free survival (LFS), relapse rate and treatment-related (non-relapse) mortality (TRM; defined as any death in the first 28 days after transplantation or any death after day 28 in continuous remission), incidence of grade II-IV acute GvHD and the presence of chronic GvHD. Surviving patients were censored at the time of last contact.
Statistical analysis
Patient-, disease-and treatment-related factors were compared between EMD and non-EMD groups, using the χ 2 -tests for categorical and MannWhitney test for continuous variables. The probability of LFS and OS were calculated using the Kaplan-Meier estimator, with the variance estimated by Greenwood's formula. Values for other endpoints were calculated using cumulative incidence curves to accommodate competing risks. 14 EMD and non-EMD groups were compared using proportional hazards regression models. Risk factors with significant level of Po0.05 in stepwise model building procedures were included in the outcome models. Potential interactions between the main effect (EMD status) and conditioning intensity, cytogenetic risk and other significant variables were examined.
RESULTS
Patient characteristics
In total, 9797 patients were identified from 310 reporting centers and 44 different countries: 814 with EMD before alloHCT (EMD group) and 8983 without EMD pre-transplant (non-EMD group). The median follow-up of survivors was 58 months (range: 3-191 months) for the EMD group and 60 months (range: 3-194 months) for the non-EMD group. Table 1 lists patient-, disease-, treatment-and transplant-related variables for all patients. Patients with EMD tended to be younger (median age of 42 vs 46 years, P o 0.001), were more likely to have a monocytic subtype (FAB M4-M5, 46 vs 29%, P o 0.001), and a higher initial WBC at diagnosis (22 vs 9, P o 0.001). The most common site of EMD was the central nervous sytem (n = 283, 35%). For other sites, 155 (19%) had skin-only and 112 (14%) possessed lymph node-only EMD. An additional 69 (8%) reported multiple sites of EMD.
Transplant conditioning regimens differed between the two groups. In the EMD group, 82% received an MA preparative regimen with 47% receiving an MA conditioning with total body irradiation compared with 75% and 35%, respectively, in the non-EMD group (P o0.001 for both comparisons). Disease status before conditioning also differed between the non-EMD and EMD groups: primary induction failure 15% versus 12%, CR1 49% versus 37%, CR2 or beyond 20% versus 26%, active relapse 17% versus 24%, respectively (P o0.001). The duration of first remission was shorter for subjects transplanted in CR2 in the EMD group versus the non-EMD group, 9 versus 11 months (P o 0.001) with 32% having a CR1 duration of o6 months compared with 19% (P o 0.001) in the non-EMD group.
Univariate analysis of outcomes Comparisons of outcomes between the EMD and non-EMD groups are listed in Table 2 . There were no significant differences in LFS or OS, the primary endpoints of our study, between patients with and without EMD in univariate analysis ( Figure 1 and Table 2 ). The 5-year LFS and OS for the EMD group was 33% (95% confidence interval (CI) 30-37%) and 36% (95% CI 32-39%), respectively. The relapse rate in the EMD groups was significantly higher at 1 year (33% versus 29%, P = 0.012) and 3 years (39% versus 34%, P = 0.022) post transplant compared with the non-EMD group. However, this risk was offset by lower rates of TRM post transplant at 3 years (24% versus 29%, P = 0.009) and 5 years (26% versus 31%, P = 0.009) in the EMD group.
For the 61 patients who proceeded to transplant with active medullary and EMD, univariate analysis showed significantly higher 3-year relapse rate, when compared with the EMD group (62% versus 39%, P = o 0.001), and significantly worse 3-year LFS (9% versus 37%, P = o0.001) and OS (10% versus 40%, P = o 0.001; Table 2 ).
Leukemia was the most common cause of death in the non-EMD group (42%) and EMD group (49%), followed by infection and GvHD (Supplementary Table 1 ). For all patients who relapsed after transplant, there were significant differences in the site of relapse (Supplementary Table 2 ). In the EMD group, 26% (14% EM site, 12% peripheral blood)/bone marrow and EM site) of patients relapsed at extramedullary sites, whereas only 9% (5% EM site, 4% peripheral blood/bone marrow and EM site) of patients in the non-EMD group relapsed at extramedullary sites. For patients transplanted in ⩾ CR2 or at relapse, 23% of the EM group relapsed solely at an EM site post transplant and 18% relapsed at both medullary and EM sites.
Multivariate analysis of outcomes Because of the poor outcomes of subjects with both EMD and active marrow disease at the time of transplant, these patients were excluded from the multivariate analysis. Notably, the presence of EMD did not affect either OS (hazard ratio 1.00, 95% CI 0.91-1.09; P = 0.91) or LFS (hazard ratio 0.98, 95% CI 0.89-1.09; P = 0.74). In addition, differences in both TRM (relative risk 0.92, 95% CI 0.80-1.06, P = 0.23) and relapse (relative risk = 1.03, 95% CI, 0.92-1.16; P = 0.62) failed to retain their significance in the multivariate model (Table 3 and Supplementary Table 4 ).
Outcome by site of EMD disease or by onset of EMD No significant differences were observed in the rate of relapse (P = 0.66; Figure 2 ) or OS based on by site of EMD (P = 0.28; Table 4 ). We compared the outcomes of the 71 patients who had an isolated granulocytic sarcoma compared with the remaining 743 patients with both EMD and marrow involvement of their leukemia (Supplementary Table 3 ). We also examined the timing of EMD onset, whether EMD was present at the time of diagnosis or at the time of transplantation. Again, in each case there was no difference in OS between these two groups (Table 4) .
Pretransplant conditioning
As the GvL effect might be weaker in EM sites, 6 we also tested for any interaction between the presence of EMD and the intensity of the conditioning regimen on the risk of relapse, which might confound our analysis. No interaction was identified between MA Abbreviations: CIBMTR = Center for International Blood and Marrow Transplant Research; CNS = central nervous sytem; CR = complete remission; EMD = extramedullary disease; MA = myeloablative; MDS = myelodysplastic syndrome; NMA = non-MA; NA = not available; RIC = reduced intensity conditioning; TBI = total body irradiation. a Other sites of EMD include: liver/spleen only, n = 45; multiple sites, n = 69; other specified, n = 150. Example of other specified: pelvic soft tissue mass, salivary gland chloroma, mass in right lung base, breast infiltrate, left mandible, gastric chloroma, bone (knee), thoracentesis fluid, polychondritis and so on. Abbreviations: aGvHD = acute GvHD; cGvHD = chronic GvHD; CI = confidence interval; DFS = disease-free survival; EMD = extramedullary disease; HCT = hematopoietic cell transplantation; LFS = leukemia-free survival; MD = medullary disease; NE = not evaluable; OS = overall survival; TRM = treatmentrelated mortality. Log-rank test: Po 0.001 for DFS, Po0.001 for OS. a Gray's test: P = 0.92 for aGvHD, P = 0.21 for cGvHD, Po 0.001 for relapse, P = 0.031 for TRM.
b
No case at risk at this time point. and reduced intensity conditioning on the risk of relapse (P = 0.1591). After MA conditioning, the relative risk of relapse was 1.09 (95% CI, 0.95-1.24; P = 0.21) and for reduced intensity conditioning was 0.89 (95% CI, 0.70-1.14; P = 0.36).
Acute and chronic GvHD At day 100, the incidence of grade II-IV acute GvHD was similar between the EMD and non-EMD groups (35% versus 36%, P = 0.60, Table 2 ). The incidence of chronic GvHD at 1, 3 and 5 years was also similar between the two groups.
DISCUSSION
This analysis of 814 patients with EM involvement of AML represents the largest and most comprehensive analysis of alloHCT outcomes in this patient population. Historically, EMD has been viewed as a poor prognostic factor, although data supporting this position are limited. For other risk factors in AML such as a monosomal karyotype and FLT3-ITD, the adverse prognostic impact persists despite alloHCT. 15, 16 Unexpectedly, when compared with a non-EMD cohort, we did not identify any impact of EMD itself on either survival, disease relapse, or TRM. In addition, the location, timing of EMD, or intensity of conditioning regimen also did not affect transplant outcomes.
As with any large retrospective registry study, there are important limitations in our analysis. The presence and location of EMD was determined by the reporting center and did not require a confirmatory pathologic or radiographic diagnosis. This may result in underreporting of EMD in locations such as lymph nodes and deep soft tissue sites that can escape detection on routine clinical examination, and over reporting in areas such as the skin, where leukemia cutis may be confused with other dermatologic conditions. At the same time, this mirrors current clinical practice in which no guidelines or standards exist for the evaluation of EMD. Abbreviations: CI = confidence interval; CR = complete remission; DLI = donor leukocyte infuction; EMD = extramedullary disease; HSCT = hematopoietic stem cell transplantation; LFS = leukemia-free survival; OS = overall survival; RR = relative risk. DLI was excluded from model. a MVA model adjusted for: WBC at diagnosis, previous history of MDS, cytogenetic risk group, disease status prior to HSCT, duration of CR1, site of relapse for patients transplanted in ⩾ CR2, time from diagnosis to HSCT, consolidation treatment, age group, conditioning regimen, type of donor, graft type, CMV serostatus, year of HSCT, GvHD prophylaxis. Abbreviations: CI = confidence interval; CNS = central nervous system; EMD = extramedullary disease; OS = overall survival.
Because of the relatively uncommon nature of EMD, we are also unable to make meaningful conclusions about specific individual cytogenetic subtypes, that is, t(8:21) or mixed lineage leukemia (MLL) rearrangements, and more uncommon sites of EMD such as testicular involvement. Molecular genetics in AML is a rapidly evolving field and the CIBMTR data set for AML is limited by lack of uniform molecular characterization of cases. For example, nucleophosmin mutations in cytogenetically normal AML confer a favorable prognosis and have been identified in 15% of isolated myeloid sarcomas through aberrant cytoplasmic localization of the protein by immunohistochemistry. 17 Based on our analysis of the CIBMTR, we found that the presence of EMD is not an independent risk factor for relapse, disease-free survival or OS in patients undergoing alloHCT. Furthermore, the outcome of patients with EMD was not influenced by the location, timing of EMD, or intensity of conditioning regimen.
